Cefepime

Cefepime is a fourth-generation cephalosporin antibiotic. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both types of organism than third-generation agents. A 2007 meta-analysis suggested when data of trials were combined, mortality was increased in people treated with cefepime compared with other β-lactam antibiotics. In response, the U.S. Food and Drug Administration (FDA) performed their own meta-analysis which found no mortality difference. Cefepime was patented in 1982 by Bristol-Myers Squibb and approved for medical use in 1994.
It is available as a generic drug and sold under a variety of trade names worldwide. It was removed from the World Health Organization's List of Essential Medicines in 2019.
Wikipedia contributors, "Cefepime", Wikipedia, revision 1373478954, retrieved 20 November 2026, source, CC BY-SA 4.0.